GlassScriptPhysician profile
Amir Taraben
NPI 1184829434
$4,731.90
in general payments reported to CMS, 2019-2025
27 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $587 · 2021: $833 · 2022: $1,316 · 2023: $781 · 2024: $520 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,497 · Travel and Lodging: $57.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,496.85 |
| Travel and Lodging | $57.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,342.16 | 2019-2024 | Optis, Coroflow, Diamondback Coronary |
| Boehringer Ingelheim Pharmaceuticals, INC. | $556.35 | 2021-2022 | |
| Abiomed | $462.66 | 2020-2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $376.66 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $305.78 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $302.22 | 2021-2025 | Lifevest |
| Boston Scientific Corporation | $239.81 | 2020-2025 | Wolverine Coronary Cutting Balloon, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $162.04 | 2021-2024 | Eliquis, Camzyos |
| Medtronic Vascular, INC. | $151.08 | 2019 | |
| Esperion Therapeutics, INC. | $123.41 | 2021 | |
| Novo Nordisk INC | $113.49 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $81.17 | 2019-2024 | Repatha |
| Medtronic, INC. | $79.66 | 2023 | Onyx Frontier, V-Loc 180 |
| Terumo Medical Corporation | $64.09 | 2019-2022 | |
| Daiichi Sankyo INC. | $52.45 | 2024-2025 | Injectafer |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $49.16 | 2020-2024 | Trapliner |
| Cardiovascular Systems INC. | $43.95 | 2019-2023 | Diamondback Coronary |
| Janssen Pharmaceuticals, INC | $41.37 | 2021-2022 | |
| Ekos Corporation | $23.99 | 2019 | |
| Biosense Webster, INC. | $23.75 | 2025 | Carto 3, Nuvision Ice Catheter |
| Pfizer INC. | $22.98 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $22.37 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $21.69 | 2025 | |
| Atricure, INC. | $20.75 | 2023 | |
| Cardiva Medical, INC. | $18.65 | 2023 | Cardiva Vascade 6/7f Vcs |
| Shockwave Medical, INC | $16.63 | 2021 | |
| Amarin Pharma, INC. | $13.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Taraben listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.